Sreedhar Subramanian

机构：St. Mark's Hospital · ORCID：0000-0002-6483-1730

发表论文 175 篇 · 总被引 3755 次 · h-index 32

代表论文

• A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 305)
• Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource (2023 · Journal of Crohn s and Colitis · 被引 119)
• Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study (2022 · Journal of Crohn s and Colitis · 被引 95)
• I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease (2022 · Clinical Gastroenterology and Hepatology · 被引 38)
• Vitamin D and COVID‐19—Revisited (2022 · Journal of Internal Medicine · 被引 30)
• Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients (2022 · Digestive Diseases and Sciences · 被引 28)